Fas ligand is expressed in normal skin and in some cutaneous malignancies

British Journal of Dermatology

Volumn 139, Issue 2, 1998, Pages 186-191

  Lee, S H ^a   Jang, J J ^b   Lee, J Y ^a   Kim, S Y ^a   Park, W S ^a   Shin, M S ^a   Dong, S M ^a   Na, E Y ^a   Kim, K M ^a   Kim, C S ^a   Kim, S H ^a   Yoo, N J ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; SKIN BIOPSY; SKIN CARCINOMA;

ADULT; ANTIGENS, CD95; ANTIGENS, SURFACE; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FAS LIGAND PROTEIN; HUMANS; IMMUNOENZYME TECHNIQUES; LIGANDS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; SKIN; SKIN NEOPLASMS;

EID: 7344233695     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02353.x     Document Type: Article

References (39)

1. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 1996; 57: 129-44.
2. Polakowska RR, Haake AR. Apoptosis: the skin from a new perspective. Cell Death Differ 1994; 1: 19-31.
3. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-78.
4. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994; 179: 873-9.
5. Itoh N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-43.
6. Nagata S. Fas ligand and immune evasion. Nat Med 1996; 2: 1306-7.
7. Bellgrau D, Gold D, Selawry H et al. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-2.
8. Griffith T, Brunner T, Fletcher S et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
9. French LE, Hahne M, Viard G et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privilege tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 335-43.
10. Hunt JS, Vassmer D, Ferguson TA, Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997; 158: 4122-8.
11. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression on Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-6.
12. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82.
13. Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med 1996; 2: 1361-6.
14. Niehans GA, Brunner T, Frizelle SP et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-12.
15. Saas P, Walker PR, Hahne M et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-8.
16. Shiraki K, Tsuji N, Shioda T et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997; 94: 6420-5.
17. Leithäuser F, Dhein J, Mechtersheimer G et al. Constitutive and induced expression of APO-1, a new member of the new growth factor/tumor necrosis receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-29.
18. Oishi M, Maeda K, Sugiyama S. Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocytes and squamous cell carcinoma cell line. Arch Dermatol Res 1994; 286: 396-407.
19. Nakajima M, Nakajima A, Kayagaki N et al. Expression of Fas ligand and its receptor in cutaneous lupus: implication in tissue injury. Clin Immunol Immunop 1997; 83: 223-9.
20. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995; 14: 1129-35.
21. Broders AC. Squamous cell epithelioma of the skin. Ann Surg 1921; 73: 141-60.
22. Backer-Cairns B, Meyers K, Hamilton R et al. Immunohistochemical staining of fixed tissue using antigen retrieval and a thermal cycler. Biotechniques 1996; 20: 641-50.
23. Kerstens HMJ, Poddighe PJ, Hansellar AGJM. A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramide. J Histochem Cytochem 1995; 43: 347-52.
24. Leverkus M, Yaar M, Gilchrest BA. Fas/Fas ligand interaction contributes to UV-induced apoptosis in human keratinocytes. Exp Cell Res 1997; 232: 255-62.
25. McGall CA, Cohen JJ. Programmed cell death in terminally differentiating keratinocytes. J Invest Dermatol 1991; 97: 111-4.
26. Norris DA. Differential control of cell death in the skin. Arch Dermatol 1995; 131: 945-8.
27. Chu BJL, Drappa J, Parnassa A, Elkon KB. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon Etn. J Exp Med 1993; 178: 723-30.
28. Fisher GH, Rosenberg FJ, Straus SE et al. Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-46.
29. Alderson MR, Armitage RJ, Maraskovsky TW et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993; 178: 2231-5.
30. Biancone L, Martino AD, Orlandi V et al. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med 1997; 186: 147-52.
31. Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res 1993; 60: 247-71.
32. Cordon-Cardo C, Fuks Z, Drobnjak M et al. Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991; 51: 6372-80.
33. Sato T, Irie S, Kituda S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411-15.
34. Owen-Schaub LB, Radinsky R, Kruzel E et al. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responses. Cancer Res 1994; 54: 1580-6.
35. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) level in nonhematopoietic human malignancy. Cancer Res 1996; 56: 3870-4.
36. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-5.
37. Costran RS. Metastasizing basal cell carcinomas. Cancer 1961; 14: 1036-40.
38. Epstein E, Epstein MM, Bragg K. Metastases from squamous cell carcinomas of the skin. Arch Dermatol 1968; 97: 245-51.
39. von Doramus H, Stevens PJ. Metastatic basal cell carcinoma. Report of live cases and review of 170 cases in the literature. J Am Acad Dermatol 1984; 10: 1043-60.